Predicted efficacy of a pharmacogenetic passport for inflammatory bowel disease.
Amber BangmaMichiel D VoskuilWerna T C Uniken VenemaHarm BruggeShixian HuPauline LantingLude H FrankeGerard DijkstraEleonora A M FestenRinse K WeersmaPublished in: Alimentary pharmacology & therapeutics (2020)
This study highlights the clinical efficacy of a pharmacogenetic passport for IBD. Implementation of such a pharmacogenetic passport into clinical management of IBD may contribute to a reduction in adverse drug responses.